← All trials
NCT01308021
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2010
- Primary completion
- Oct 1, 2011
- Completion date
- Dec 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 202
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- ASIT Biotech S.A.Lead sponsor
- AZ Sint-LucasOverall official - principal investigator
- CHR WarquigniesOverall official - principal investigator
- CH de DinantOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- University of LilleOverall official - principal investigator
- University of StrasbourgOverall official - principal investigator
- University of ReimsOverall official - principal investigator
- Centre Hospitalier de LuxembourgOverall official - principal investigator
- Universitair Ziekenhuis GentOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Free University of BrusselsOverall official - principal investigator
- University of AntwerpOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.